Leukemias: Our Clinical Trials

Here you can find a continually updated listing of Memorial Sloan Kettering's current clinical trials for adults with leukemia. To learn more about a study, choose from the list below.

For clinical trials for children with leukemia, please visit Pediatric Clinical Trials.

You can also visit our Blood & Marrow Stem Cell Transplantation Clinical Trials.

Showing 37 trials
Title Investigatorsort icon
A Phase III Randomized Study of Expanded Umbilical Cord Blood Cells to Enhance Blood System Recovery in Patients with Hematologic Cancers Undergoing Stem Cell Transplantation
[Protocol 13-214]
Barker, Juliet, MBBS
A Reduced Intensity Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients with Acute Leukemia or Myelodysplasia
[Protocol 08-087]
Barker, Juliet, MBBS
A Phase III Study of Sapacitabine in Elderly Patients Newly Diagnosed with Acute Myeloid Leukemia
Newly Diagnosed
[Protocol 12-034]
Berman, Ellin, MD
A Phase II Study of Treatment-Free Remission in Chronic-Phase Chronic Myelogenous Leukemia Patients Who Achieve and Sustain a Complete Molecular Response After Switching to Nilotinib
[Protocol 13-152]
Berman, Ellin, MD
A Phase II Study of a Pediatric-Inspired Combination Chemotherapy Regimen in Adults with Acute Lymphoblastic Leukemia
[Protocol 12-266]
Douer, Dan, MD
A Phase I Study of ABT-199 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma
Relapsed/Refractory
[Protocol 11-152]
Gerecitano, John, MD, PhD
A Phase II Study of Palifermin with or without Leuprolide After T-Cell-Depleted Allogeneic Stem Cell Transplantation
[Protocol 12-077]
Goldberg, Jenna, MD
A Phase I Study of PRT062070 in Patients with Persistent or Recurrent Chronic Lymphocytic Leukemia, Small Cell Lymphocytic Leukemia, or B-Cell Non-Hodgkin Lymphoma
[Protocol 14-023]
Hamlin, Paul, MD
A Phase II Study of KW-0761 or Standard Therapy in Patients with Previously Treated Adult T-Cell Leukemia-Lymphoma
[Protocol 12-251]
Horwitz, Steven, MD
A Phase I Study of HDM201 in Patients with Advanced Cancers and a Normal TP53 Gene
[Protocol 14-139]
Hyman, David, MD
A Study Assessing the Use of Dual Handset Phones to Improve Communication with Inpatients Who Have Limited English Proficiency
[Protocol 14-042]
Kumar, Chhavi, MD
A Phase I Study of Nivolumab (BMS-936558) in Patients with Relapsed or Refractory Hematologic Cancers
Relapsed/Refractory
[Protocol 12-142]
Lesokhin, Alexander, MD
A Phase II Trial of a WT-1 Vaccine in Patients with Acute Myeloid Leukemia
[Protocol 10-143]
Maslak, Peter, MD
A Phase I/II Study of Oral Azacitidine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes after Receiving a Stem Cell Transplant from a Donor
[Protocol 13-160]
Papadopoulos, Esperanza, MD
A Phase II Study of Midostaurin to Prevent Relapse After Allogeneic Stem Cell Transplantation in Patients with FLT3-ITD Mutated Acute Myeloid Leukemia
[Protocol 13-242]
Papadopoulos, Esperanza, MD
A Study of Posaconazole Versus Micafungin to Protect Against Invasive Fungal Infections in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia or Myelodysplastic Syndrome
[Protocol 10-038]
Papanicolaou, Genovefa, MD
A Phase II Study of Tretinoin plus Arsenic Trioxide in Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Therapy
[Protocol 11-040]
Park, Jae, MD
A Phase I/II Study of Low-Dose Cytarabine and Lintuzumab-Ac-225 in Older Patients with Previously Untreated Acute Myeloid Leukemia
Newly Diagnosed
[Protocol 09-053]
Park, Jae, MD
A Phase II Study of Vemurafenib in Patients with Relapsed or Refractory Hairy Cell Leukemia
Relapsed/Refractory
[Protocol 12-200]
Park, Jae, MD
A Phase III Study of Inotuzumab Ozogamicin versus Standard Therapy in Patients with Persistent or Recurrent CD22-Positive Acute Lymphoblastic Leukemia
Relapsed/Refractory
[Protocol 12-262]
Park, Jae, MD
A Phase I Study of Genetically Modified T Cells to Treat Recurrent or Refractory Chronic Lymphocytic Leukemia
[Protocol 06-138]
Park, Jae, MD
A Phase I Trial of B-Cell Acute Lymphoblastic Leukemia Treated with Autologous T Cells Gene-Targeted to the B-Cell Antigen CD19
Relapsed/Refractory
[Protocol 09-114]
Park, Jae, MD
A Phase I Study of Consolidation Therapy with Autologous T Cells Genetically Targeted to CD19 in Patients with Chronic Lymphocytic Leukemia After Initial Chemotherapy
[Protocol 11-048]
Park, Jae, MD
A Phase I/II Study Assessing BPX-501 T Cells Given After Partially Mismatched Related T Cell-Depleted Stem Cell Transplantation in Patients with Hematologic Cancers
[Protocol 13-181]
Perales, Miguel-Angel, MD
A Phase II Study of AUY922 in Patients with Myelofibrosis
Newly Diagnosed & Relapsed/Refractory
[Protocol 12-076]
Rampal, Raajit, MD
A Phase I Study of SGN-CD33A in Patients with CD33-Positive Acute Myeloid Leukemia
[Protocol 13-137]
Stein, Eytan, MD
A Phase I Study of AG-221 in Patients with Advanced Acute Myeloid Leukemia or Myelodysplastic Syndromes with an IDH2 Mutation
[Protocol 13-154]
Stein, Eytan, MD
A Phase I/II Study of PLX3397 to Treat Patients with Acute Myeloid Leukemia that Has Returned or Persisted Despite Therapy
Relapsed/Refractory
[Protocol 13-204]
Stein, Eytan, MD
A Phase I Study of Oral AG-120 to Treat Advanced Acute Myeloid Leukemia or Myelodysplastic Syndromes with an IDH1 Mutation
[Protocol 14-052]
Stein, Eytan, MD
A Phase I/II Study of GSK525762 in Patients with Persistent Hematologic Cancers
[Protocol 13-202]
Stein, Eytan, MD
A Phase I Study of CPI-0610 in Patients with Acute Leukemia, Myelodysplastic Syndromes, or Myelodysplastic/Myeloproliferative Neoplasms
[Protocol 14-136]
Stein, Eytan, MD
A Phase III Study of Clofarabine versus Standard Therapy for Newly Diagnosed Acute Myeloid Leukemia in Older Adults
Newly Diagnosed
[Protocol 12-059]
Tallman, Martin, MD
A Phase I Study of EPZ-5676 in Patients with Relapsed/Refractory Leukemia and Other Advanced Hematologic Cancers
[Protocol 12-181]
Tallman, Martin, MD
Exercise and Quality Diet After Leukemia: The EQUAL Study
[Protocol 14-164]
Tonorezos, Emily, MD, MPH
A Phase III Study of Bendamustine and Rituximab plus GS-1101 (CAL-101) or Placebo for Previously Treated Chronic Lymphocytic Leukemia
[Protocol 12-189]
Zelenetz, Andrew, MD, PhD
A Phase II Study of CAL-101 plus Rituximab in Elderly Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
[Protocol 10-224]
Zelenetz, Andrew, MD, PhD
A Phase Ib Study of Urelumab Given with Rituximab in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Relapsed/Refractory
[Protocol 13-252]
Zelenetz, Andrew, MD, PhD